The Philadelphia Chromosome provided the first evidence that genetic abnormalities were linked to cancer. This discovery at Penn Medicine more than 50 years ago ushered in the modern period of cytogenetics. Now, the Center for Personalized Diagnostics (CPD) builds on this legacy and is set to pave the way for a new era of genomic and therapeutic pathology. The Center is a joint initiative with the Abramson Cancer Center and integrates molecular genetics, pathology informatics and genomic pathology to empower physicians and patients to truly customize their treatment options accordingly. Host Dr. Lee Freedman welcomes Dr. David Roth, Chair of the Department of Pathology and Laboratory Medicine and Simon Flexner Professor of Pathology and Laboratory Medicine at Penn Medicine to discuss the unique Center and offerings for patients.